114 related articles for article (PubMed ID: 32590338)
21. In vivo evaluation of the effects of simultaneous inhibition of GLUT-1 and HIF-1α by antisense oligodeoxynucleotides on the radiosensitivity of laryngeal carcinoma using micro 18F-FDG PET/CT.
Shen LF; Zhao X; Zhou SH; Lu ZJ; Zhao K; Fan J; Zhou ML
Oncotarget; 2017 May; 8(21):34709-34726. PubMed ID: 28410229
[TBL] [Abstract][Full Text] [Related]
22. Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS.
Iwamoto M; Kawada K; Nakamoto Y; Itatani Y; Inamoto S; Toda K; Kimura H; Sasazuki T; Shirasawa S; Okuyama H; Inoue M; Hasegawa S; Togashi K; Sakai Y
J Nucl Med; 2014 Dec; 55(12):2038-44. PubMed ID: 25453050
[TBL] [Abstract][Full Text] [Related]
23. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
[TBL] [Abstract][Full Text] [Related]
24. The use of 18F-Fluoro-deoxy-glucose positron emission tomography (18F-FDG PET) as a non-invasive pharmacodynamic biomarker to determine the minimally pharmacologically active dose of AZD8835, a novel PI3Kα inhibitor.
Maynard J; Emmas SA; Ble FX; Barjat H; Lawrie E; Hancox U; Polanska UM; Pritchard A; Hudson K
PLoS One; 2017; 12(8):e0183048. PubMed ID: 28806782
[TBL] [Abstract][Full Text] [Related]
25. High iodine effects on the proliferation, apoptosis, and migration of papillary thyroid carcinoma cells as a result of autophagy induced by BRAF kinase.
Zhang D; Xu X; Li J; Yang X; Sun J; Wu Y; Qiao H
Biomed Pharmacother; 2019 Dec; 120():109476. PubMed ID: 31563816
[TBL] [Abstract][Full Text] [Related]
26. Co-inhibition of SMAD and MAPK signaling enhances 124I uptake in BRAF-mutant thyroid cancers.
Luckett KA; Cracchiolo JR; Krishnamoorthy GP; Leandro-Garcia LJ; Nagarajah J; Saqcena M; Lester R; Im SY; Zhao Z; Lowe SW; de Stanchina E; Sherman EJ; Ho AL; Leach SD; Knauf JA; Fagin JA
Endocr Relat Cancer; 2021 May; 28(6):391-402. PubMed ID: 33890869
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism of glucose by extrahepatic bile duct cancer cells.
Yoon SO; Jeon TJ; Park JS; Ryu YH; Lee JH; Yoo JS; Kim JK; Yoon DS; Oh EJ
Clin Nucl Med; 2015 Mar; 40(3):e178-82. PubMed ID: 25608150
[TBL] [Abstract][Full Text] [Related]
28. Mitogen-Activated Protein Kinase Pathway Inhibition for Redifferentiation of Radioiodine Refractory Differentiated Thyroid Cancer: An Evolving Protocol.
Iravani A; Solomon B; Pattison DA; Jackson P; Ravi Kumar A; Kong G; Hofman MS; Akhurst T; Hicks RJ
Thyroid; 2019 Nov; 29(11):1634-1645. PubMed ID: 31637953
[No Abstract] [Full Text] [Related]
29. High 18F-FDG uptake in PMAH correlated with normal expression of Glut1, HK1, HK2, and HK3.
Cavalcante IP; Zerbini MC; Alencar GA; Mariani Bde P; Buchpiguel CA; Almeida MQ; Mendonca BB; Fragoso MC
Acta Radiol; 2016 Mar; 57(3):370-7. PubMed ID: 25766729
[TBL] [Abstract][Full Text] [Related]
30. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
31. 18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Sachpekidis C; Kopp-Schneider A; Hakim-Meibodi L; Dimitrakopoulou-Strauss A; Hassel JC
Melanoma Res; 2019 Apr; 29(2):178-186. PubMed ID: 30653029
[TBL] [Abstract][Full Text] [Related]
32. Hyperactive ERK and persistent mTOR signaling characterize vemurafenib resistance in papillary thyroid cancer cells.
Hanly EK; Tuli NY; Bednarczyk RB; Suriano R; Geliebter J; Moscatello AL; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2016 Feb; 7(8):8676-87. PubMed ID: 26735176
[TBL] [Abstract][Full Text] [Related]
33. Complete Metabolic Response of Advanced Melanoma to Vemurafenib Assessed with FDG-PET-CT at 85 Hours.
Pascal P; Dercle L; Weyts K; Meyer N; Courbon F
Clin Nucl Med; 2018 May; 43(5):333-334. PubMed ID: 29485438
[TBL] [Abstract][Full Text] [Related]
34. Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.
Cullinane C; Waldeck KL; Binns D; Bogatyreva E; Bradley DP; de Jong R; McArthur GA; Hicks RJ
Nucl Med Biol; 2014 Feb; 41(2):148-54. PubMed ID: 24332383
[TBL] [Abstract][Full Text] [Related]
35. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
[TBL] [Abstract][Full Text] [Related]
36. 2-[18F]-2-deoxy-D-glucose (FDG) uptake in human tumor cells is related to the expression of GLUT-1 and hexokinase II.
Ong LC; Jin Y; Song IC; Yu S; Zhang K; Chow PK
Acta Radiol; 2008 Dec; 49(10):1145-53. PubMed ID: 18979289
[TBL] [Abstract][Full Text] [Related]
37. Platelet-derived growth factor receptor-α promotes lymphatic metastases in papillary thyroid cancer.
Zhang J; Wang P; Dykstra M; Gelebart P; Williams D; Ingham R; Adewuyi EE; Lai R; McMullen T
J Pathol; 2012 Oct; 228(2):241-50. PubMed ID: 22744707
[TBL] [Abstract][Full Text] [Related]
38. VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer.
Chen S; Su X; Jiang X; Zhang T; Min I; Ding Y; Wang X; Mao Z; Cao J; Teng X; Fahey TJ; Wang W; Teng L
Transl Oncol; 2020 Feb; 13(2):441-451. PubMed ID: 31911278
[TBL] [Abstract][Full Text] [Related]
39. mTOR inhibitors sensitize thyroid cancer cells to cytotoxic effect of vemurafenib.
Hanly EK; Bednarczyk RB; Tuli NY; Moscatello AL; Halicka HD; Li J; Geliebter J; Darzynkiewicz Z; Tiwari RK
Oncotarget; 2015 Nov; 6(37):39702-13. PubMed ID: 26284586
[TBL] [Abstract][Full Text] [Related]
40. Relationship between 18F-FDG accumulation and lactate dehydrogenase A expression in lung adenocarcinomas.
Zhou X; Chen R; Xie W; Ni Y; Liu J; Huang G
J Nucl Med; 2014 Nov; 55(11):1766-71. PubMed ID: 25342384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
